Unsafe
Not Aligned
Patient Risk:
High
Summary
Most interaction and study-specific quantitative claims (e.g., % increases for warfarin/digoxin/erythromycin) are not supported by the provided Lipitor prescribing information excerpts. Several statements are only partially aligned with label excerpts (muscle toxicity risk with cyclosporine and general CYP3A4 inhibition), and others are unsupported or not verifiable from the supplied text.
Category Scores
Accurate Statements
Pharmacokinetic interactions involve one medication affecting how another is absorbed, distributed, metabolized, or excreted.
Not addressed in the provided label excerpts.
Pharmacodynamic interactions involve one medication affecting how another works in the body.
Not addressed in the provided label excerpts.
Synergistic interactions involve two or more medications working together to produce a greater effect than the sum of their individual effects.
Not addressed in the provided label excerpts.
Unsupported Statements
Taking Lipitor (atorvastatin) with warfarin can increase the risk of bleeding.
The provided Lipitor label excerpts do not mention warfarin/bleeding.
A study reported atorvastatin increased warfarin's anticoagulant effect by 25%.
No warfarin study or 25% figure is present in the provided excerpts.
Lipitor (atorvastatin) can increase digoxin levels in the blood.
No digoxin-related interaction is present in the provided excerpts.
In a study, atorvastatin increased digoxin levels by 20%.
No digoxin study/percentage is present in the provided excerpts.
Lipitor (atorvastatin) can increase the risk of muscle damage when taken with fibrates (e.g., gemfibrozil).
The provided excerpts do not mention fibrates (gemfibrozil) or an interaction risk statement for them.
A study reported atorvastatin increased the risk of muscle damage when taken with gemfibrozil.
No gemfibrozil study or muscle-damage figure is present in the provided excerpts.
Lipitor (atorvastatin) can increase levels of certain antibiotics in the blood (e.g., erythromycin).
The provided excerpts discuss clarithromycin (not erythromycin) and only with CYP3A4 inhibitor AUC/caution wording.
In a study, atorvastatin increased erythromycin levels by 30%.
No erythromycin study/percentage is present in the provided excerpts.
Lipitor (atorvastatin) can increase tacrolimus levels in the blood, which can lead to toxicity.
No tacrolimus interaction is present in the provided excerpts.
Lipitor (atorvastatin) can decrease rifampin levels in the blood, which can lead to reduced efficacy.
No rifampin interaction is present in the provided excerpts.
The article states that Lipitor interactions can be serious and potentially life-threatening.
The provided excerpts include serious rhabdomyolysis/myopathy and caution language but do not include the specific 'life-threatening' framing as a general statement about interactions.
The article states the most common Lipitor interactions include warfarin, digoxin, fibrates, and antibiotics.
The provided excerpts do not identify 'most common' interactions or list these as such.
The article states other medications to avoid with Lipitor include cyclosporine, tacrolimus, and rifampin.
The provided excerpts only specify a dose limit for cyclosporine; tacrolimus and rifampin are not mentioned as avoid-listed drugs in the provided excerpts.
Contradictions
Important Omissions
Label-specific interaction details for listed agents with exact guidance (e.g., cyclosporine dose limit: LIPITOR dose should not exceed 10 mg when co-administered).
Importance:
Moderate
A statement that cyclosporine interaction is managed by a maximum atorvastatin dose (not a generalized 'increase levels leading to toxicity' claim).
Importance:
Moderate
Specific label-based safety counseling about myopathy/rhabdomyolysis risk and when to discontinue or temporarily withhold (e.g., markedly elevated CPK; risk factor predisposing to renal failure secondary to rhabdomyolysis).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Multiple interaction claims are not supported by the provided label excerpts and include quantitative % figures and drug pairings (e.g., warfarin, digoxin, gemfibrozil, erythromycin, tacrolimus, rifampin) absent from the supplied prescribing information. This could mislead readers about actual on-label interaction risks and required precautions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most drug-interaction statements (including study-specific percentages and several drug pairings) are unsupported by the provided FDA label excerpts, while the label-specific cyclosporine guidance is not accurately incorporated.
Suggested Improvement
Remove or qualify unsupported interaction claims and numeric study outcomes not present in the provided label excerpts. Align interactions only to what is explicitly in the supplied labeling (e.g., cyclosporine dose limit; caution with strong CYP3A4 inhibitors such as clarithromycin/itraconazole/protease inhibitors; grapefruit juice note; and general myopathy/rhabdomyolysis warning and discontinuation/withholding criteria).